News from Pharmacy Times

News from Pharmacy Times, a full-service pharmacy media resource. It provides clinically based and practical information including medication errors, drug interactions, patient education, pharmacy technology, disease state management, patient counseling, product news, pharmacy law and health-system pharmacy to a large audience of retail pharmacists (over 1.3 million) in the United States.


New Prostate Cancer Drug Gets FDA OK

Officials with the FDA approved apalutamide (Erleada) for the treatment of patients with non-metastatic, castration-resistant prostate cancer, according to a press release. Apalutamide is the first drug approved for non-metastatic, castration-resistant prostate cancer. “In the trial supporting approval, Erleada had a robust effect on this endpoint. This demonstrates the agency’s […]


FDA Approves Castration-Sensitive Prostate Cancer Drug

Officials with the FDA have granted approval to abiraterone acetate (Zytiga) tablets in combination with prednisone for the treatment of metastatic high-risk castration-sensitive prostate cancer (CSPC), according to a press release. Abiraterone acetate previously gained FDA approval in 2011 for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) who had […]


Combination Therapy That Includes Daratumumab Lowers Risk of Multiple Myeloma Progression

Patients with newly diagnosed multiple myeloma showed a lower risk of disease progression or death with daratumumab (Darzalex, Janssen) added to the standard regimen of bortezomib (Velcade, Takeda), melphalan and prednisone, in a recent study, than patients who were treated without daratumumab in their drug combination.1 Phase 3 trial results recently […]


FDA OKs 2 Fixed Dose HIV Treatments

Officials with the FDA have approved 2 different fixed dose drugs indicated to treat HIV-1: Symfi Lo tablets and Biktarvy. Symfi Lo tablets are a combination of efavirenz (EFV) 400-mg, lamivudine (3TC) 300-mg, tenofovir disoproxil fumarate (TDF) 300-mg. Biktarvy is a combination of bictegravir, emtricitabine, and tenofovir alafenamide. Symfi Lo Symfi Lo is […]


AVYCAZ Approved to Treat HABP/VABP

The US Food and Drug Administration has approved Allergan’s supplemental New Drug Application to expand the approved use of their cephalosporin / beta-lactamase inhibitor combo antibiotic, AVYCAZ (ceftazidime and avibactam), to include the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the following susceptible Gram-negative microorganisms: Klebsiella […]